Atherosclerotic plaque rupture - Local or systemic process?

被引:110
作者
Lutgens, E [1 ]
van Suylen, RJ [1 ]
Faber, BC [1 ]
Gijbels, MJ [1 ]
Eurlings, PM [1 ]
Bijnens, AP [1 ]
Cleutjens, KB [1 ]
Heeneman, S [1 ]
Daemen, MJAP [1 ]
机构
[1] Univ Maastricht, Cardiovasc Res Inst Maastricht, Dept Pathol, NL-6229 HX Maastricht, Netherlands
关键词
atherosclerosis; inflammation; pathology;
D O I
10.1161/01.ATV.0000097783.01596.E2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is generally established that the unstable plaque is the major cause of acute clinical sequelae of atherosclerosis. Unfortunately, terms indicating lesions prone to plaque instability, such as "vulnerable plaque," and the different phenotypes of unstable plaques, such as plaque rupture, plaque fissuring, intraplaque hemorrhage, and erosion, are often used interchangeably. Moreover, the different phenotypes of the unstable plaque are mostly referred to as plaque rupture. In the first part of this review, we will focus on the definition of true plaque rupture and the definitions of other phenotypes of plaque instability, especially on intraplaque hemorrhage, and discuss the phenotypes of available animal models of plaque instability. The second part of this review will address the pathogenesis of plaque rupture from a local and a systemic perspective. Plaque rupture is thought to occur because of changes in the plaque itself or systemic changes in the patient. Interestingly, contributing factors seem to overlap to a great extent and might even be interrelated. Finally, we will propose an integrative view on the pathogenesis of plaque rupture.
引用
收藏
页码:2123 / 2130
页数:8
相关论文
共 107 条
[1]   TRIGGERING OF PLAQUE DISRUPTION AND ARTERIAL THROMBOSIS IN AN ATHEROSCLEROTIC RABBIT MODEL [J].
ABELA, GS ;
PICON, PD ;
FRIEDL, SE ;
GEBARA, OC ;
MIYAMOTO, A ;
FEDERMAN, M ;
TOFLER, GH ;
MULLER, JE .
CIRCULATION, 1995, 91 (03) :776-784
[2]   Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study [J].
Albert, MA ;
Danielson, E ;
Rifai, N ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (01) :64-70
[3]   Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score [J].
Albert, MA ;
Glynn, RJ ;
Ridker, PM .
CIRCULATION, 2003, 108 (02) :161-165
[4]   Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis [J].
Angelillo-Scherrer, A ;
de Frutos, PG ;
Aparicio, C ;
Melis, E ;
Savi, P ;
Lupu, F ;
Arnout, J ;
Dewerchin, M ;
Hoylaerts, MF ;
Herbert, M ;
Collen, D ;
Dahlbäck, B ;
Carmeliet, P .
NATURE MEDICINE, 2001, 7 (02) :215-221
[5]   CORONARY ATHEROSCLEROTIC PLAQUES WITH AND WITHOUT THROMBUS IN ISCHEMIC HEART SYNDROMES - A MORPHOLOGICAL, IMMUNOHISTOCHEMICAL, AND BIOCHEMICAL-STUDY [J].
ARBUSTINI, E ;
GRASSO, M ;
DIEGOLI, M ;
PUCCI, A ;
BRAMERIO, M ;
ARDISSINO, D ;
ANGOLI, L ;
DESERVI, S ;
BRAMUCCI, E ;
MUSSINI, A ;
MINZIONI, G ;
VIGANO, M ;
SPECCHIA, G .
AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (07) :B36-B50
[6]   Vasculin, a novel vascular protein differentially expressed in human atherogenesis [J].
Bijnens, APJJ ;
Gils, A ;
Jutten, B ;
Faber, BCG ;
Heeneman, S ;
Kitslaar, PJEHM ;
Tordoir, JHM ;
de Vries, CJM ;
Kroon, AA ;
Daemen, MJAP ;
Cleutjens, KBJM .
BLOOD, 2003, 102 (08) :2803-2810
[7]   Evidence of hypoxic areas within the arterial wall in vivo [J].
Björnheden, T ;
Levin, M ;
Evaldsson, M ;
Wiklund, O .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (04) :870-876
[8]   Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease [J].
Blankenberg, S ;
Rupprecht, HJ ;
Poirier, O ;
Bickel, C ;
Smieja, M ;
Hafner, G ;
Meyer, J ;
Cambien, F ;
Tiret, L .
CIRCULATION, 2003, 107 (12) :1579-1585
[9]   Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina [J].
Blankenberg, S ;
Tiret, L ;
Bickel, C ;
Peetz, D ;
Cambien, F ;
Meyer, J ;
Rupprecht, HJ .
CIRCULATION, 2002, 106 (01) :24-30
[10]   von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis [J].
Blann, AD ;
McCollum, CN .
BLOOD COAGULATION & FIBRINOLYSIS, 1999, 10 (06) :375-380